Singapore Exchange (SGX) today welcomed Biolidics Limited to its Catalist under the stock code “8YY”.
Biolidics Limited is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for the treatment of cancer. These applications include cancer diagnosis, prognosis, treatment selection and treatment monitoring. Biolidics Limited is an associated company of Catalist-listed Clearbridge Health.
Mohamed Nasser Ismail, Head of Equity Capital Market (SME) and Head of Capital Market Development, SGX, said, “Singapore houses one of the region’s biggest medical technology clusters and is at the forefront of many developments on the medical front. Biolidics joins the growing number of medtech companies looking to tap Asia’s healthcare market and SGX looks forward to supporting the company as it further explores opportunities in diagnostics and other specialties.”
Executive Director and CEO of Biolidics Limited, Mr. Ivan Lew, said, “With Biolidics' novel patented technology to separate and enrich cancer cells from blood, there is great potential for Biolidics’ chances to grow and successfully exploit the opportunities in the cancer diagnostics industry. While Biolidics is entering a new phase with our listing on SGX, we will continue to use our collective passion and dedication to develop the Company and create value to our stakeholders.”
With a market capitalisation of about S$68 million, the listing of Biolidics Limited brings the total number of companies listed on Catalist to 214, with a combined market capitalisation of more than S$10 billion. This listing will also strengthen SGX’s healthcare cluster, which will now have 40 companies, with combined market capitalisation of more than S$70 billion.
Biolidics Limited opened at S$0.265 today.
